Skip to main content
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1999 Sep;65(3):671–679. doi: 10.1086/302530

Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.

A Dørum 1, K Heimdal 1, E Hovig 1, M Inganäs 1, P Møller 1
PMCID: PMC1377973  PMID: 10441573

Abstract

For genetic counseling and predictive testing in families with inherited breast-ovarian cancer, penetrances and expressions of the underlying mutations should be known. We have previously reported two BRCA1 founder mutations in the Norwegian population. Index cases for the present study were found two different ways: through a series of consecutive ovarian cancers (n=16) and through our family cancer clinic (n=14). Altogether, 20 of the patients had BRCA1 1675delA, and 10 had 1135insA. Their relatives were described with respect to absence/presence of breast and/or ovarian cancer. Of 133 living female relatives, 83 (62%) were tested for the presence of a mutation. No difference, in penetrance and expression, between the two mutations were found, whereas differences according to method of ascertainment were seen. The overall findings were that disease started to occur at age 30 years and that by age 50 years 48% of the mutation-carrying women had experienced breast and/or ovarian cancer. More ovarian cancers than breast cancers were recorded. Both penetrance and expression (breast cancer vs. ovarian cancer) were different from those in reports of the Ashkenazi founder mutations. Whether the reported differences reflect true differences and/or methodological problems is discussed. An observed excess of mutation carriers could not be accounted for by methodological problems; possible explanations were a "true" low penetrance or preferential segregation.

Full Text

The Full Text of this article is available as a PDF (237.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen T. I., Børresen A. L., Møller P. A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet. 1996 Aug;59(2):486–487. [PMC free article] [PubMed] [Google Scholar]
  2. Dørum A., Møller P., Kamsteeg E. J., Scheffer H., Burton M., Heimdal K. R., Maehle L. O., Hovig E., Tropé C. G., van der Hout A. H. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. Eur J Cancer. 1997 Dec;33(14):2390–2392. doi: 10.1016/s0959-8049(97)00328-6. [DOI] [PubMed] [Google Scholar]
  3. Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed] [Google Scholar]
  4. Fodor F. H., Weston A., Bleiweiss I. J., McCurdy L. D., Walsh M. M., Tartter P. I., Brower S. T., Eng C. M. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998 Jul;63(1):45–51. doi: 10.1086/301903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gayther S. A., Warren W., Mazoyer S., Russell P. A., Harrington P. A., Chiano M., Seal S., Hamoudi R., van Rensburg E. J., Dunning A. M. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995 Dec;11(4):428–433. doi: 10.1038/ng1295-428. [DOI] [PubMed] [Google Scholar]
  6. Katsouyanni K., Signorello L. B., Lagiou P., Egan K., Trichopoulos D. Evidence that adult life risk factors influence the expression of familial propensity to breast cancer. Epidemiology. 1997 Sep;8(5):592–595. doi: 10.1097/00001648-199709000-00019. [DOI] [PubMed] [Google Scholar]
  7. Levy-Lahad E., Catane R., Eisenberg S., Kaufman B., Hornreich G., Lishinsky E., Shohat M., Weber B. L., Beller U., Lahad A. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  8. Liede A., Tonin P. N., Sun C. C., Serruya C., Daly M. B., Narod S. A., Foulkes W. D. Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet. 1998 Jan 6;75(1):55–58. doi: 10.1002/(sici)1096-8628(19980106)75:1<55::aid-ajmg12>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  9. Narod S. A., Ford D., Devilee P., Barkardottir R. B., Lynch H. T., Smith S. A., Ponder B. A., Weber B. L., Garber J. E., Birch J. M. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):254–264. [PMC free article] [PubMed] [Google Scholar]
  10. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES